X

Drug Profile

Ketoprofen transdermal - IDEA AG

Alternative Names: Diractin; IDEA-033

Latest Information Update: 02 Oct 2021

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator IDEA
Developer Alpharma; IDEA
Class Analgesics; Antirheumatics; Nonsteroidal anti-inflammatories; Phenylpropionates; Small molecules
Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Registered Musculoskeletal pain
Discontinued Pain

Most Recent Events

31 Dec 2008 Alpharma has been acquired by King Pharmaceuticals
24 Jul 2008 IDEA AG withdraws an MAA with the EMEA for Musculoskeletal pain
10 Feb 2008 Phase-III clinical trials in Pain in USA (Transdermal)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com